American Heart Month Is Going Strong

February is American Heart Month, sponsored by the American Heart Association. We also celebrated Go Red for Women, which raised awareness for the sex differences in heart disease. With that in mind, we have compiled a list of our breakdowns of the latest research and highlights of what you need to know.

Rosuvastatin, 20 mg/day, can improve the coagulation profile of patients with venous thrombosis (VT).

This 28-day randomized clinical trial of rosuvastatin found that participants taking the study drug had substantially improved FVIII:C, von Willebrand factor:Ag, FVII:C, FXI:C, and D-dimer levels than participants not taking rosuvastatin. Read more

Canagliflozin decreases the risk for heart failure (HF) and other cardiovascular (CV) events, compared with dipeptidyl peptidase-4 inhibitors.

This 30-month analysis included adults with type 2 diabetes who had initiated canagliflozin or a non-gliflozin antidiabetic agent. Results showed that participants taking canagliflozin had fewer hospital admissions for heart attack and stroke. Read more

Omega-3 fatty acids may not lower the risk for coronary heart disease (CHD) or any major CV events after all.

Current recommendations suggest omega-3 fatty acid supplements for the prevention of CHD and other CV conditions. However, this review found no support for these recommendations. Read more

For more cardiology news, visit our Medical Resource Center at https://www.consultant360.com/topic/cardiology.